Your referrals are vital to this important clinical study.
Wait! Before you prescribe…
Many medications such as ACE inhibitors are prohibited during the study (see the full list on this page), and may eliminate a dog from qualifying, or delay enrollment in the study. So you’ll want to refrain from prescribing excluded medications to your canine patients whose owners are interested in study participation. All dogs in the study receive the test medication, so there is no chance your enrolled patient will go untreated.
We are currently enrolling dogs diagnosed with ACVIM Stage B2 MMVD to evaluate an investigational medication to determine whether it may delay the onset of CHF.
This is an FDA-regulated study with benefits for you, your patient, and your client.
How do I refer a patient?
Call the study site in your area. Tell them you would like to refer a patient to the “Dog Heart Study,” and they will walk you through the referral process.
Once the referral process is complete, have your client call the Study Site to schedule a screening appointment.
Eligible canine patients you refer remain in your regular care while receiving a full year of specialty care overseen by veterinary cardiologists.
All study participants receive the investigational medication, not a placebo. The investigational medication is now in the final stage of testing before submission to the FDA.
You can be confident your patients will receive quality care and benefits, including up to a $500 credit to spend at your clinic once your patient’s participation is complete.
In order to ensure you receive payment of client credits at your hospital, please complete and forward an Acknowledgement Form and W-9 Tax Form to us and ensure each participating dog owner completes this short form.
- A moderate to high intensity systolic heart murmur with maximal intensity over the mitral area (≥ grade 3/6).
- Echocardiographic evidence of MMVD defined as characteristic valvular lesions of the mitral valve apparatus (leaflet thickening, valve prolapse, ruptured chordae tendinae).
- Presence of mitral regurgitation on the color Doppler echocardiogram.
- Echocardiographic evidence of left atrial dilatation, i.e. 2D left atrial/aortic (LA/Ao) ratio ≥ 1.8 by the Swedish method.
- Radiographic evidence of cardiomegaly (vertebral heart size [VHS] score > 10.5).
- Dogs must be at least 6 years of age.
- Dogs must have a body weight between 4.1 kg and 15 kg (9 lb and 33.1 lb).
- Current or previous evidence of cardiogenic pulmonary edema.
- Clinically significant supraventricular and/or ventricular tachyarrhythmia (i.e. requiring antiarrhythmic therapy).
- Current or previous evidence of clinically significant coughing that interferes with the clinical assessment of progressing clinical signs.
- Current or previous evidence of syncope.
- Cardiac disease other than MMVD disease (excluding concurrent tricuspid insufficiency where disease of the mitral valve is considered to be the more significant abnormality).
- Known significant systemic or other organ-related disease that will limit the dog’s life expectancy or requires chronic treatment (See prohibited medications below.) Dogs with hypothyroidism may be included provided the Investigator deems them clinically stable on pharmacotherapy.
- Evidence of clinically relevant pulmonary hypertension (right atrial: right ventricular [RA:RV]) gradient > 65 mmHg).
- Pretreatment for cardiovascular disease with any agent on the prohibited medication list below.
- Pregnant or lactating.
Prohibited concomitant medications*
*All commercially available topical treatments for ears and eyes are allowed even if some ingredients are found in the table below.
|ACE-Inhibitors||enalapril, benazepril, captopril, fosinopril, imidapril, lisinopril, ramipril|
|Angiotensin II receptor blockers||candesartan, telmisartan|
|Antiarrhythmics||lidocaine, bretylium, flecainide, mexiletine, procainamide, phenytoin, propafenone, quinidine, tocainide, beta-blockers, [atenolol, bisoprolol, carvedilol, esmolol, metoprolol, nadolol, propranolol], amiodarone, sotalol, Ca++ channel blockers [diltiazem, verapamil], digoxin, digitoxin|
|Anticholinergics||atropine, glycopyrrolate, propantheline|
|Beta-blockers||atenolol, bisoprolol, carvedilol, esmolol, metoprolol, nadolol, propranolol|
|Diuretics||furosemide, hydrochlorothiazide, thiazides, chlorothiazide, torasemide, spironolactone, epleronone|
|Phosphodiester ase V inhibitors||sildenafil, tardalafil|
|Positive inotropes||levosimendan, milrinone, isoproterenol, dobutamine, dopamine, digoxin, digitoxin|
|Pressor agents||epinephrine, norepinephrine, phenylephrine|
|Vasodilators (including nitric oxide donors)||amoldipine, hydralazine, prazosin, nitroglycerine (including topical), isosorbide di-/mononitrate, other nitrates, nitric oxide, sodium nitroprusside, L-arginine|
|Other||iloprost, epoprostenol, bosentan known cardiotoxins (e.g. adriamycin)|
Permitted concomitant medications
|Bronchodilators||aminophylline, theophylline, terbutaline|
|Antibiotics||All antibiotics allowed|
|Other||corticosteroids, cough suppressants, mirtazapine or other appetite stimulants, and anti-seizure medications|